EIF2AK1 and EIF2AK2 encode members of the Eukaryotic Translation Initiation Factor 2 Alpha Kinase (EIF2AK) family that inhibits protein synthesis in response to physiologic stress conditions. EIF2AK2 is also involved in innate immune response and the regulation of signal transduction, apoptosis, cell proliferation, and differentiation. Despite these findings, human disorders associated with deleterious variants in EIF2AK1 and EIF2AK2 have not been reported. Here, we describe the identification of eight unrelated individuals with heterozygous de novo missense variants in EIF2AK1 (1/8) or EIF2AK2 (7/8). Features seen in these eight individuals include white matter alterations (8/8), developmental delay (8/8), impaired language (8/8), cognitive impairment (7/8), ataxia (6/8), dysarthria in probands with verbal ability (6/6), hypotonia (6/8), hypertonia (5/8), and involuntary movements (3/8). Individuals with EIF2AK2
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The Eukaryotic Translation Initiation Factor 2 Alpha Kinase (EIF2AK) family is comprised of four mammalian kinases that regulate the cytoprotective integrated stress response (ISR) required for cellular adaptation to stress conditions 1; 2 . EIF2AK1 (MIM: *613635; HGNC: 24921), also known as Heme-Regulated Inhibitor, responds to heme deprivation, proteasome inhibition, and maintains basal endoplasmic reticulum (ER) stress [3] [4] [5] [6] [7] . EIF2AK1 contains two protein kinase domains and two heme binding sites. EIF2AK2 (MIM: *176871; HGNC: 9437), also known as Protein Kinase R (PKR), is activated by double-stranded RNA (dsRNA) and can block the translation of viral mRNA in response to infection [8] [9] [10] , activation also occurs in response to oxidative stress, ER stress [11] [12] [13] [14] , cytokines 14; 15 , and growth factors 16 . EIF2AK2 contains two dsRNA binding motifs (DSRM) and a protein kinase domain. In the presence of their respective cellular stressors, both EIF2AK1 or EIF2AK2 activate ISR by phosphorylating Eukaryotic Translation Initiation Factor 2 Subunit 1 (EIF2S1, also known as EIF2a), a major regulator of the initiation of mRNA translation and the rate of protein synthesis. Phosphorylation of EIF2S1 on serine 51 by EIF2AK family members prevents mRNA translation and result in transient suppression of general protein synthesis 17; 18 . Prior studies have linked missense, nonsense, and splicing variants in EIF2AK3 and truncating variants in EIF2AK4 to autosomal recessive epiphyseal dysplasia with early onset diabetes mellitus (OMIM #226980) and autosomal recessive pulmonary veno-occlusive disease type 2 (OMIM #234810), respectively 19; 20 . Neither of these disorders present with primary neurologic findings. However, the phenotypic consequences of rare variants in human EIF2AK1 and EIF2AK2 are currently unknown.
Through the Undiagnosed Diseases Network 25; 26 , curation of ~13,500 clinical exome sequencing (ES) from Baylor Genetics (BG), and GeneMatcher 21; 22 , we identified multiple unrelated individuals with consistent clinical symptoms, abnormal magnetic resonance imaging (MRI) findings in the brain and/or spinal cord (Figure 1A-F) , and rare de novo missense variants in either EIF2AK1 or EIF2AK2. Eight individuals were enrolled into our study. All had rare missense variants in either EIF2AK1 or EIF2AK2 and were identified via trio ES with Sanger sequencing confirmation. The variants localize to the protein kinase or DSRM domains of EIF2AK1 and EIF2AK2 [9] [10] [11] (Fig2A, B) . Additionally, we identified a rare missense variant in EIF2AK2 (c.341T>A, p.Leu114Gln) of unknown inheritance from a proband-only ES in a patient with discordant phenotypes. We included the EIF2AK2 p.Leu114Gln variant in the molecular studies as a rare variant control. All of the variants were absent from the Exome Aggregation Consortium Database 23 and the Genome Aggregation Database (gnomAD) 24; 27 .
All individuals with EIF2AK1 or EIF2AK2 variants had motor delay (8/8), speech and language delay (8/8), and abnormal white matter findings in the central nervous system (8/8 Statistical models examining observed versus expected functional coding variation reveal that EIF2AK1 and EIF2AK2 undergo selective restraint, a process where selection has reduced functional variation, suggesting that missense variants are more likely to be deleterious 24 . Analysis of the observed to the expected loss-of-function (LoF) variation across the genes for EIF2AK1 and EIF2AK2 revealed observed/expected (o/e) scores of 0.47 and 0.30, respectively. These o/e results indicate that there is less LoF variation than predicted 24 .
Additionally, the Residual Variation Intolerance Score version 4 (RVISv4) is -0.331 for EIF2AK1 and -1.2108 for EIF2AK2, where RIVS < 0 indicates there is less common functional variation in the population than predicted 29 . Finally, both EIF2AK1 and EIF2AK2 have low probability of LoF intolerance scores (pLI = 0 and 0.06, respectively) in gnomAD 24 . Based on the gene size and GC content, 34 (EIF2AK1) and 32 (EIF2AK2) LoF variants were expected, and in the gnomAD population 16 (EIF2AK1) and 9 (EIF2AK2) LoF variants were observed 24 . Together, these statistical findings indicate that EIF2AK1 and EIF2AK2 likely are haplosufficient, but are less tolerant of missense variants.
To determine the functional consequences of the de novo variants identified in EIF2AK1 and EIF2AK2, we cloned full-length human wildtype (WT) EIF2AK1, EIF2AK2, and unrelated control cDNAs into the mammalian expression vector pcDNA-DEST40. This vector allows for expression of C-terminal V5 (GKPIPNPLLGLDSD) tagged proteins (EIF2AK1-WT-V5 and EIF2AK2-WT-V5) by a CMV promoter. The pcDNA-DEST40 cDNA constructs were transfected into two human cell lines, HEK293T and HeLa. There was a modest level of EIF2AK1-WT-V5 and EIF2AK2-WT-V5 overexpression compared to an unrelated protein-V5 control (Fig2C), suggesting that EIF2AK1 and EIF2AK2 protein levels are tightly regulated in these cell lines.
Overexpression of EIF2AK1-WT-V5 also reduced the total EIF2AK2 protein level (Fig2C, D).
Next, to determine the consequences of EIF2AK1 or EIF2AK2 LoF, we examined the impact of either EIF2AK1 or EIF2AK2 knockdown on EIF2S1 phosphorylation (p-EIF2S1) in HEK293T cells or HeLa cells. We designed three independent siRNAs targeting different regions of To test if the EIF2AK1 and EIF2AK2 variants are deleterious, we generated pcDNA-DEST40 cDNA constructs to express the human variants in HEK293T or HeLa cells. The variants were generated via either Agilent QuikChange Lightning or NEB Q5 site-directed mutagenesis and confirmed by Sanger sequencing. We assessed the effects of the EIF2AK1 and EIF2AK2 variants on protein kinase activity and protein stability in both mammalian cell lines and available patient-derived skin fibroblasts. First, we examined whether the EIF2AK1 and EIF2AK2 variants altered protein kinase activity in HEK293T cells. We found that overexpression of EIF2AK1-WT-V5 in HEK293T cells upregulated p-EIF2S1 levels. However, overexpression of EIF2AK1-Ile448Val-V5 had no effect on p-EIF2S1 levels, indicating that the EIF2AK1 p.Ile448Val variant impairs protein kinase activity (Fig3A). Unlike the EIF2AK1 findings, overexpression of either WT EIF2AK2 or variants tested in this study had no effect on p-EIF2S1 levels in HEK293T or HeLa cells (Fig3B, i). This finding is consistent with our previous observation that EIF2AK2 knockdown in HEK293T and HeLa cells had no effect on p-EIF2S1 levels (Fig2E), suggesting that HEK293T and HeLa cells are insensitive to altered EIF2AK2 protein level.
Second, we examined whether the EIF2AK2 variants affected the expression of EIF2AK2 protein in HEK293T (Fig3B, i-iii) and HeLa (data not shown) cells by using a V5 antibody to probe for the exogenous protein and an EIF2AK2 antibody to probe for the total EIF2AK2 protein. Interestingly, we found that nearly all EIF2AK2 variants (p.Tyr133Phe, p.Ala109Val, p.Gly325Ser, and p.Ser461Cys) in our cohort had reduced total and V5-tagged EIF2AK2 protein expression. In comparison, the rare variant control EIF2AK2 p.Leu114Gln, which we identified in a proband with discordant phenotype from our curation of the BG sequencing database, had no reduction in protein levels compared to EIF2AK2 WT (Fig3B, iiii). To examine whether the reduced EIF2AK2 protein stability associated with the p.Tyr133Phe, p.Ala109Val, p.Gly325Ser, and p.Ser461Cys variants was the result of impaired EIF2S1 signaling on general protein translation, we performed co-transfection with an unrelated protein, MAP1LC3A, tagged with GFP-RFP (GFP-RFP-MAP1LC3A). The co-transfection of EIF2AK2 variants with GFP-RFP-MAP1LC3A had no effect on GFP-RFP-MAP1LC3A levels, indicating that overexpression of EIF2AK2 variants in HEK293T or HeLa cells does not affect general protein translation (Fig3B, ii).
Based on our findings that HEK293T and HeLa cells are insensitive to EIF2AK2 overexpression or knockdown, we obtained three independent patient-derived fibroblast lines heterozygous for EIF2AK2 p.Met11Leu, p.Tyr133Phe, and Ser461Cys. First, we examined the levels of EIF2S1 phosphorylation in the fibroblast lines and found a consistent reduction in p-EIF2S1 levels in all three lines (Fig3C). EIF2AK2 protein levels were stable in the heterozygous patient-derived skin fibroblast lines (Fig3D), indicating that the reduced p-EIF2S1 levels were likely due to impaired EIF2AK2 kinase activity. Next, we examined whether EIF2AK2 kinase activity can be stimulated in the heterozygous fibroblast lines by inducing cellular stress through the addition of polyinosinic:polycytidylic acid (poly-IC). Poly-IC is structurally similar to dsRNA, which is present in some viruses, and can activate the ISR pathway through EIF2S1 phosphorylation by EIF2AK family members 30 . Incubation with poly-IC activates Toll-like receptor 3 (TLR3), which recognizes dsRNA 31 , and the activated TLR3 recruits TRAF6, TAK1, and TAB2 to form the TAK1-complex [32] [33] [34] . EIF2AK2 is present in the poly-IC induced TAK1complex and expression of a kinase inactive EIF2AK2 mutant protein inhibits poly-IC induction of the TLR3-mediated signaling pathway 32 . Furthermore, poly-IC stimulation of mammalian cells has been shown to upregulate the EIF2AK2-mediated phosphorylation of EIF2S1 10; 35; 36 .
Together these findings suggest that poly-IC stimulation of mammalian cells triggers both a primary TLR3-mediated signaling event and a secondary EIF2Ak2-mediated signaling event following poly-IC uptake into cells 10 . Therefore, to test the functional consequences of the We were unable to test the poly-IC induction in the heterozygous EIF2AK2 p.S461C fibroblasts as the line failed to expand after a few passages. Together, these results demonstrate that EIF2AK2 p.Met11Leu, p.Tyr133Phe, and Ser461Cys impair the EIF2AK2 kinase activity required for EIF2S1 phosphorylation in fibroblasts.
The results of our clinical and molecular characterizations in mammalian cell lines and patient-derived fibroblasts show that EIF2AK1 or EIF2AK2 missense variants at key functional domains lead to neurodevelopmental disorders with overlapping symptoms. The EIF2AK1 p.Ile448Val, EIF2AK2 p.Met11Leu, EIF2AK2 p.Tyr133Phe, and EIF2AK2 p.Ser461Cys variants that we tested in either mammalian cell lines or patient-derived skin fibroblasts showed reduced kinase activity with impaired EIF2S1 phosphorylation.
Comparing genotypes and phenotypes within the cohort reveals several findings of interest. First, proband 1 with a de novo EIF2AK1 p.Ile448Val variant has a distinct motorpredominant phenotype compared to the rest of the cohort with de novo EIF2AK2 variants. suggesting that EIF2AK1 is more tolerant than EIF2AK2 to LoF mutations. Therefore, the phenotypic spectrum associated with EIF2AK1 variants may be milder than for EIF2AK2 variants or there may be incomplete penetrance of EIF2AK1 pathogenic variants. However, this determination is limited by the small sample size. Second, of the seven probands with de novo EIF2AK2 missense variants, proband 2 is the only individual without a history of neurologic decompensation in the setting of fevers and illnesses. Although the reason for a relatively milder phenotype associated with the EIF2AK2 p.Met11Leu variant remains unclear, it is possible the p.Met11Leu variant is less damaging as it did not reduce EIF2AK2 protein levels when overexpressed in mammalian cell lines.
Our functional data reveal that the de novo missense variants impair EIF2AK1 or EIFAK2 kinase activity and lead to reduced EIF2S1 phosphorylation. This impact on EIF2S1 activity would interfere with downstream molecular pathways critical for responding to cellular stressors. An abnormal stress response may underlie the neurologic decompensation and corresponding white matter alterations associated with fevers and illnesses in our cohort.
Potential pathogenic mechanisms for these variants include gain-of-function, haploinsufficiency, and dominant-negative. A gain-of-function mechanism is less likely given the EIF2S1 phosphorylation and protein stability data, as well as the impaired response to poly-IC stimulation in fibroblasts. Haploinsufficiency may not be the sole contributor to the observed phenotypes in our probands given that LoF variants are present in gnomAD 24 , a family with thoracic aortic aneurysm syndrome was found to have a heterozygous deletion of chromosome 2p22.3-p22.2 involving EIF2AK2 and 10 other genes 37 , and mouse models with constitutive loss of either Eif2ak1 or Eif2ak2 are viable and fertile without gross morphological abnormalities or neurologic findings 38; 39 . These findings are all consistent with EIF2AK1 and EIF2AK2 pLI scores of 0 and 0.06, respectively 24 , indicating that they are haplosufficient. Given that EIF2AK1 and EIF2AK2 require dimerization to phosphorylate their downstream target, a possible mechanism is that the de novo missense variants are dominant-negative mutations affecting the function of the wildtype protein.
The phosphorylation of EIF2S1 converts EIF2S1 into a competitive inhibitor of EIF2B, which activates the ISR 40 . Therefore, the impaired EIF2S1 phosphorylation we observed with the de novo EIF2AK1 and EIF2AK2 missense variants would likely impact the EIF2B-mediated regulation of the ISR. Pathogenic variants in any of the five genes encoding the subunits of the EIF2B protein complex (EIF2B1, EIF2B2, EIF2B3, EIF2B4, and EIF2B5) are associated with autosomal recessive childhood ataxia with central nervous system hypomyelination/vanishing white matter disease (CACH/VWM, MIM #603896) [41] [42] [43] [44] [45] In conclusion, we have shown that pathogenic EIF2AK1 and EIF2AK2 missense variants cause a broad phenotypic spectrum including developmental delays, variable cognitive impairments, hypotonia, hypertonia, involuntary movements, ataxia, and white matter alterations. Individuals with EIF2AK2 variants also exhibit sensitivity to febrile illness and commonly experience neurological regression, similar to CACH/VWM. The phenotypic overlap between CACH/VWM and our probands with de novo missense EIF2AK1 and EIF2AK2 variants suggest that deleterious missense variants in EIF2AK1 and EIF2AK2 cause an autosomal dominant neurodevelopmental syndrome that may share common pathogenic mechanisms with CACH/VWM disease.
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